ArticleCurrent infectious disease reports2008
Current status of tight blood sugar control.
Article in Current infectious disease reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Blood glucose control using a computer-guided glucose management system in allogeneic hematopoietic cell transplant recipients.Bone marrow transplantation · 2016Article
- Early neurological deterioration after subarachnoid haemorrhage: risk factors and impact on outcome.Journal of neurology, neurosurgery, and psychiatry · 2013Article
- Systemic glucose and brain energy metabolism after subarachnoid hemorrhage.Neurocritical care · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review describes the current status and the clinical data related to the effects of tight glucose control in critically ill patients. In contrast to decreases in mortality and morbidity reported in one study in which insulin rate was titrated to keep blood glucose between 80 and 110 mg/dL, the benefits were not confirmed in multicenter prospective studies. Retrospective data found an association between a mean blood glucose level below 140 to 150 mg/dL and improved outcome. Currently unanswered issues include the optimal target for blood glucose, effects of blood glucose variability, hazards of hypoglycemia, and potential influence of the underlying disorder on the effects of tight glucose control. Therefore, recommendations regarding practical aspects of tight glucose control by intensive insulin therapy cannot be supported by currently available data. An intermediate target level for blood glucose of 140 to 180 mg/dL seems associated with the lowest risk-to-benefit ratio.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.